Acute Kidney Injury News and Research

RSS

Acute kidney injury (AKI) involves sudden damage to the kidneys or decrease in renal function that occurs over a few hours or days. The severity of the condition can vary from a minor loss of kidney function to kidney failure.

Consumer group calls for ban on weight loss drugs Alli and Xenical

According to the consumer watchdog Public Citizen, the weight loss drugs Alli and Xenical should be removed from the market because of the growing risk of side effects that include liver damage, pancreatitis and kidney stones.

15 Apr 2011

Klotho hormone can protect kidney from renal fibrosis

A natural hormone known to inhibit aging can also protect kidneys against renal fibrosis, UT Southwestern Medical Center researchers have demonstrated.

15 Apr 2011

Study finds AKIN criteria effective in cirrhosis detection

The first clinical study investigating the use of the AKIN criteria in cirrhosis has shown significant benefits that have the potential to change future diagnosis, according to results from a Spanish study presented today at the International Liver Congress.

1 Apr 2011

CorMedix reports encouraging interim results from CRMD001 phase II study in Contrast Induced Acute Kidney Injury

CorMedix Inc., a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiorenal disease, today announced its interim analysis and clinical update for CRMD001.

1 Apr 2011

Gadavist approved by FDA for use in central nervous system MRI scans

The U.S. Food and Drug Administration approved Gadavist (gadobutrol), a gadolinium-based contrast agent, for use in patients undergoing magnetic resonance imaging (MRI) of the central nervous system.

16 Mar 2011

Depression is linked with increased risk of developing kidney failure

Depression is associated with an increased risk of developing kidney failure in the future, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society Nephrology.

10 Mar 2011

Bayer's gadobutrol injection for CNS imaging receives FDA Advisory Committee approval

Bayer HealthCare Pharmaceuticals Inc. announced today that the Peripheral and Central Nervous System Drugs Advisory Committee to the U.S. Food and Drug Administration voted unanimously that clinical trial and postmarketing data for gadobutrol injection, a macrocyclic 1.0 molar gadolinium-based contrast agent (GBCA), support approval of the product for proposed use in diagnostic magnetic resonance imaging (MRI) in adults and children.

24 Jan 2011

Silence provides year-end update on trading and offer-period

Silence Therapeutics plc, a leading global biotechnology company dedicated to the discovery, development and delivery of targeted, systemic RNA interference (RNAi) therapeutics for the treatment of serious diseases, today provides a year-end update on trading and the offer-period.

21 Dec 2010

German Research Foundation opens four new research units

The Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) is establishing four new Research Units. The decision was made by the DFG Senate at its December session in Bonn. The establishment of the Research Units will enable researchers to explore prevailing topical questions and generate new approaches in their respective fields.

15 Dec 2010

Elevated levels of MCP-1 found in urine of patients with acute kidney injury

The presence of certain markers in the urine might be a red flag for acute kidney injury (AKI), according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology (JASN). The results suggest that a simple urine test could help prevent cases of kidney failure.

12 Nov 2010

ADRCs cells improve survival in acute kidney injury animal model

Preclinical data was published today on research performed by Cytori Therapeutics (NASDAQ:CYTX) showing adipose (fat)-derived stem and regenerative cells (ADRCs), either fresh or banked, demonstrated statistically significant improvements in animal survival and kidney function in an acute kidney injury animal model.

6 Oct 2010

Covidien supports FDA labeling changes for gadolinium-based contrast agents

Covidien, a leading global provider of healthcare products, today announced it supports the U.S. Food and Drug Administration's (FDA) labeling changes for gadolinium-based contrast agents for patients with acute kidney injury or chronic, severe kidney disease.

13 Sep 2010

GBCAs carry new warnings on their labels about risk of NSF: FDA

The U.S. Food and Drug Administration is requiring that gadolinium-based contrast agents (GBCAs) carry new warnings on their labels about the risk of a rare and potentially fatal condition known as nephrogenic systemic fibrosis, if the drug is administered to certain patients with kidney disease.

10 Sep 2010

Quark Pharmaceuticals announces option agreement with Novartis for QPI-1002 siRNA drug

Silence Therapeutics plc, a leading international RNAi therapeutics company, is pleased to note that its partner, Quark Pharmaceuticals, Inc., has announced the grant of an option to Novartis to obtain an exclusive worldwide license to develop and commercialise QPI-1002, a p53 temporary inhibitor siRNA drug which incorporates Silence's AtuRNAi technology.

20 Aug 2010

Quark enters licensing option agreement with Novartis for p53 temporary inhibitor siRNA drug QPI-1002

Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, today announced that it has granted Novartis an option to obtain an exclusive worldwide license to develop and commercialize its p53 temporary inhibitor siRNA drug QPI-1002, currently the subject of a Phase II clinical trial.

18 Aug 2010

Strategies for AKI prevention are possible, study results suggest

Reduced kidney function and protein in the urine place a person at risk for kidney injury, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology. The results suggest that improved recognition of these warning signs could help reduce preventable forms of acute kidney injury.

30 Jul 2010

CorMedix announces dosing of first patient with CRMD-001 in Phase II clinical trial

CorMedix Inc., a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of Cardiorenal disease, today announced dosing of the first patient with CRMD-001 (a proprietary formulation of deferiprone) in a randomized, double-blind, placebo-controlled clinical trial.

25 Jun 2010

Researchers treat acute kidney injury using cells genetically reprogrammed to produce protein

A protein whose primary role is in the embryonic development of kidneys may play a future role in treating kidney failure. Indiana University School of Medicine researchers have successfully treated acute kidney injury in laboratory experiments using cells that were genetically reprogrammed to produce the protein. The research suggests there could be a potential future treatment using such cells delivered intravenously instead of surgically.

23 Jun 2010

AKI patients admitted to hospital on a weekend more likely to die: Study

Patients with acute kidney injury who are admitted to the hospital on a weekend are more likely to die than those admitted on a weekday, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology. This disparity was most evident in smaller hospitals.

16 Apr 2010

FDA accepts for review Abbott's novel diagnostic test for rapid detection of NGAL

A novel diagnostic test to rapidly detect neutrophil gelatinase-associated lipocalin (NGAL), an early biomarker that identifies patients at risk for acute kidney injury (AKI), has been accepted for review by the United States Food and Drug Administration. If approved, this would be the first test available for use in the United States for the detection of NGAL.

1 Apr 2010